Dose the first child with achondroplasia in the BEACH301 study
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Nov 2024
- Due
- 31 Mar 2025
- Delivered
- August 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“TYRA expects to dose the first child with achondroplasia in BEACH301 in Q1 2025.”
What we found
Evidence strength A What the grades mean
The company did not dose the first child in the BEACH301 study by the Q1 2025 deadline, instead announcing in August 2025 that the first child had been dosed.
-
A Tyra Biosciences, Inc. 10-Q filed 2025-11-05
“We dosed the first child in this study in August 2025.” ✓ confirmed on the page
-
A Tyra Biosciences, Inc. 10-K filed 2026-03-02
“In August 2025, we announced that the first child was dosed in BEACH301” ✓ confirmed on the page
Market reaction: the shares moved -3.9% against the S&P 500 over the three sessions around the disclosure (4 Nov 2025 to 7 Nov 2025). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +183 days
- 3 versions
-
Version 1 · original · stated 7 Nov 2024
Deadline 31 Mar 2025 (“in Q1 2025”) · wording expected
-
Version 2 · stated 27 Mar 2025
Deadline 30 Jun 2025 (“Q2 2025”)
“BEACH301: dose first child with achondroplasia with TYRA-300 – Q2 2025”
-
Version 3 · stated 14 Aug 2025
Deadline 30 Sep 2025 (“3Q 2025”)
“BEACH301: dose first child with achondroplasia – 3Q 2025”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Dose
- Deliverable
- First child dosed in BEACH301
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Tyra Biosciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-TYRA-002081 · Corrections policy